8-K
Atrium Therapeutics to Present Nonclinical Data for ATR 1072 in PRKAG2 Syndrome at AHA Scientific Sessions 2026
8-K
Atrium Therapeutics Doses First Patient in Phase 1/2 Corventis Trial for PRKAG2 Syndrome
8-K/A
Amendment Corrects Shares Outstanding Following $[PIPE Offering] Sale of Common Stock and Pre-Funded Warrants
8-K
Atrium Therapeutics Announces $50 Million Private Placement
8-K
Atrium Therapeutics Reports Second Quarter 2026 Financial Results and Clinical Progress
8-K
Atrium Therapeutics Announces FDA Clearance of IND Application for ATR 1072 to Treat PRKAG2 Syndrome
